Radiotherapy Quality Assurance Report from Children's Oncology Group AHOD0031
Overview
Authors
Affiliations
Purpose: A phase 3 trial assessing response-based therapy in intermediate-risk Hodgkin lymphoma mandated real-time central review of involved field radiation therapy (IFRT) and imaging records by a centralized review center to maximize protocol compliance. We report the impact of centralized radiation therapy review on protocol compliance.
Methods And Materials: Review of simulation films, port films, and dosimetry records was required before and after treatment. Records were reviewed by study-affiliated or review center-affiliated radiation oncologists. A deviation of 6% to 10% from protocol-specified dose was scored as "minor"; a deviation of >10% was "major." A volume deviation was scored as "minor" if margins were less than specified or "major" if fields transected disease-bearing areas. Interventional review and final compliance review scores were assigned to each radiation therapy case and compared.
Results: Of 1712 patients enrolled, 1173 underwent IFRT at 256 institutions in 7 countries. An interventional review was performed in 88% of patients and a final review in 98%. Overall, minor and major deviations were found in 12% and 6% of patients, respectively. Among the cases for which ≥1 pre-IFRT modification was requested by the Quality Assurance Review Center and subsequently made by the treating institution, 100% were made compliant on final review. By contrast, among the cases for which ≥1 modification was requested but not made by the treating institution, 10% were deemed compliant on final review.
Conclusions: In a large trial with complex treatment pathways and heterogeneous radiation therapy fields, central review was performed in a large percentage of cases before IFRT and identified frequent potential deviations in a timely manner. When suggested modifications were performed by the institutions, deviations were almost eliminated.
Luo L, Xue W, Qumseya A, Vasquez J, Venkatramani R, Wolden S J Clin Oncol. 2024; 42(36):4263-4270.
PMID: 39255438 PMC: 11652240. DOI: 10.1200/JCO.24.00928.
Quality improvements in radiation oncology clinical trials.
Smith K, Ulin K, Knopp M, Kry S, Xiao Y, Rosen M Front Oncol. 2023; 13:1015596.
PMID: 36776318 PMC: 9911211. DOI: 10.3389/fonc.2023.1015596.
Quality assurance in radiation oncology.
Fitzgerald T, Followill D, Laurie F, Boterberg T, Hanusik R, Kessel S Pediatr Blood Cancer. 2021; 68 Suppl 2:e28609.
PMID: 33818891 PMC: 10578132. DOI: 10.1002/pbc.28609.
A dedicated cloud system for real-time upfront quality assurance in pediatric radiation therapy.
Meroni S, Cavatorta C, Barra S, Cavagnetto F, Scarzello G, Scaggion A Strahlenther Onkol. 2019; 195(9):843-850.
PMID: 31025053 DOI: 10.1007/s00066-019-01469-y.
Breneman J, Donaldson S, Constine L, Merchant T, Marcus K, Paulino A Int J Radiat Oncol Biol Phys. 2018; 101(4):860-874.
PMID: 29976498 PMC: 6548440. DOI: 10.1016/j.ijrobp.2018.03.002.